Analyst Note
| Damien Conover |AstraZeneca reported solid first-quarter results slightly above our expectations, but we don’t expect any major change to our fair value estimate. While COVID-19 product sales were down as expected with the pandemic receding, core products continue to post solid growth while the pipeline is making excellent strides to reinforce the firm’s wide moat.